Interleukin-6 Receptor Antagonist [EPC]

75608 reported adverse events

Drugs of this class: SARILUMAB TOCILIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-6 Receptor Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 27731
1 RHEUMATOID ARTHRITIS 16247
2 PAIN 13351
3 ARTHRALGIA 10561
4 OFF LABEL USE 10405
5 JOINT SWELLING 9790
6 FATIGUE 9057
7 DRUG INTOLERANCE 8436
8 RASH 8283
9 CONTRAINDICATED PRODUCT ADMINISTERED 7739
See all common reactions for Interleukin-6 Receptor Antagonist [EPC]

Drugs of the Interleukin-6 Receptor Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 271 0.9313
1 RED BLOOD CELL SEDIMENTATION RATE 161 0.8944
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 2301 0.8908
3 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 62 0.8857
4 DISABILITY ASSESSMENT SCALE SCORE INCREASED 181 0.8660
5 SWOLLEN JOINT COUNT INCREASED 441 0.8630
6 PEMPHIGUS 4483 0.8351
7 RHEUMATOID FACTOR NEGATIVE 131 0.7988
8 RHEUMATOID FACTOR POSITIVE 2022 0.7871
9 RHEUMATIC FEVER 522 0.7791
See all enriched reactions for Interleukin-6 Receptor Antagonist [EPC]